Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients

NCT: NCT04559334 · SUSPENDED

NCT IDNCT04559334
StatusSUSPENDED
Start Date2020-12-21
Completion2027-12-31

Brief Summary

In this research study we want to learn more about a study drug, tetrasodium sodium EDTA (Kitelock™) for maintaining the patency (blood flow) through a central venous catheter. Catheter occlusions such as blood clots have been shown to increase the risk of central line-associated bloodstream infection (CLABSI). This treatment consists of instilling a daily a dose of a solution , similar to heparin or saline lock flushes, into the catheter when it is not in use. The aim is to prevent CLABSI without increasing complications such as catheter breakage.

Frequently Asked Questions

What is Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients?

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients is a clinical trial registered under NCT04559334. Current status: SUSPENDED.

What is the status of NCT04559334?

The current status of NCT04559334 (Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients) is: SUSPENDED.

When did Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients start?

Compassionate-Use of 4% T-EDTA Lock Solution for Central Venous Lines of Pediatric PN Patients started on 2020-12-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑